Optimal diabetes management during medical weight loss for cardiovascular risk reduction

References

• Flegal KM, Carrol MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288(14), 1723–1727 (2002).
   Google Scholar
• Lloyd-Jones DM, Liu K, Colangelo LA, Yan LL, Klein L. Consistently stable body mass index and changes in risk factors associated with the metabolic syndrome. Circulation (2004) (Abstract 3567).
   Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Maggio C, Pi-Sunyer X. Obesity and Type 2 diabetes. Endocrinol. Metab. Clin. N. Am. 32, 805–822 (2003).
   PubMed Web of Science ®Google Scholar
• Cho E, Manson J, Stampfer M et al. A prospective study of obesity and risk of coronary heart disease among diabetic women. Diabetes Care 25, 1142–1148 (2002).
   PubMed Web of Science ®Google Scholar
• Must A, Spadano J, Coakly EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 282, 1523–1529 (1999).
   PubMed Web of Science ®Google Scholar
• DECODE Study Group; on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 161, 397–405 (2001).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Howard, B, Smith S et al. Prevention Conference IV: Diabetes and cardiovascular disease. Circulation 105, 2231–2239 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in Type 2 diabetes: review with meta-analysis of clinical studies. J. Am. Coll. Nutr. 22(5), 331–339 (2003).
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX. Comorbidities of overweight and obesity: current evidence and research issues. Med. Sci. Sports Exerc. 31, S602–S608 (1999).
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX. Medical hazards of obesity. Ann. Intern. Med. 119, 655–660 (1993).
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 162, 1867–1872 (2002).
   PubMed Web of Science ®Google Scholar
• Krauss RM, Winston M, Fletcher RN, Grundy SM. Obesity: impact of cardiovascular disease. Circulation 98, 1472–1476 (1998).
   Google Scholar
• Franz MJ, Bantle JP, Beebe CA et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 26(Suppl.), S51–S61 (2003).
   PubMedGoogle Scholar
• Dixon JB, O’Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laproscopic adjustable gastric banding. Diabetes Care 25, 358–363 (2002).
   PubMed Web of Science ®Google Scholar
• Frank A. Futility and avoidance. Medical professionals in the treatment of obesity. JAMA 269, 2132–2133 (1993).
   PubMed Web of Science ®Google Scholar
• National Institute ofHealth/National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Obes. Res. 651S–209S. (1998).
   Google Scholar
• Plodkowski R, St. Jeor S. Medical nutrition therapy for the treatment of obesity. Endocrinol. Metab. Clin. N. Am. 32, 935–965 (2003).
   Google Scholar
• ADA Standards of Medical Care in Diabetes – Position Statement. Diabetes Care 28(Suppl. 1) S4–S36 (2005).
   PubMed Web of Science ®Google Scholar
• Klein S, Sheard N, Pi-Sunyer X et al. Weight management through lifestyle modification for the prevention and management of Type 2 diabetes: rational and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Am. J. Clin. Nutr. 80, 257–263 (2004).
   PubMed Web of Science ®Google Scholar
• Krauss RM, Eckel RH, Howard B et al. AHA dietary guidelines: revison 2000. A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102, 2284–2299 (2000).
   PubMed Web of Science ®Google Scholar
• National CholesterolEducation Program. Executive summary of the third report of the National Cholesterol Education Program expert panel on selection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).
   Google Scholar
• National Institutesof Health, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH, MD, USA (1998).
   Google Scholar
• Tsai A, Wadden T. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann. Intern. Med. 142, 55–66 (2004).
   Google Scholar
• Wadden TA, Forester GD, Letizia KA. One-year behavioral treatment of moderate and severe caloric restriction and the effects of weight maintenance therapy. J. Consult. Clin. Psychol. 62, 165–171 (1994).
   PubMed Web of Science ®Google Scholar
• Yang H, Petersen GM, Roth M-P et al. Risk factors for gallstone formation during rapid loss of weight. Dig. Dis. Sci. 37, 912–918 (1995).
   Google Scholar
• Saris WH. Very-low-calorie diets and sustained weight loss. Obes Res. 9(Suppl. 4), 295S–301S (2001).
   Google Scholar
• Anderson JW, Kong EC, Fredric ARC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am. J. Clin. Nutr. 74, 579–584 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson JW, Luan J, Hoie LH. Structured weight-loss programs: meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity. Adv. Ther. 21, 61–75 (2004).
   Google Scholar
• Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 83, 25F–29F (1999)
   PubMed Web of Science ®Google Scholar
• Koutsari C, Hardman AE. Exercise prevents the augmentation of postprandial lipaemia attributable to low-fat high-carbohydrate diet. Br. J. Nutr. 86(2), 197–206 (2001).
   Google Scholar
• Seshadri P, Iqbal N, Stern L, Williams M et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am. J. Med. 117, 498–405 (2004).
   Google Scholar
• Meckling KA, O’Sullivan C, Saari D. Comparison of a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living overweight men and women. J. Clin. Endocrinol. Metab. 89, 2717–2723 (2004).
   PubMed Web of Science ®Google Scholar
• Pitsovos C, Panagiotakos DB, Chrysohoou C et al. The effect of Mediterranean Diet on the risk of the development of acute coronary syndromes in hypercholesterol-emic people: a case control study (CARDIO2000). Coron. Artery Dis. 13, 295–300 (2003).
   Google Scholar
• Trichopoulou A, costacou T, Bamia C et al. Adherence to a Mediterranean Diet and survival in Greek Population. N. Engl. J. Med. 348, 2599–2608 (2003).
   PubMed Web of Science ®Google Scholar
• Heilbronn LK, Noakes M, Clifton PM. Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with Type 2 diabetes. Diabetes Care 22, 889–895 (1999).
   PubMedGoogle Scholar
• Mattes RD. Ready-to-eat cereal used as a meal replacement promotes weight loss in humans. J. Am. Coll. Nutr. 21, 570–577 (2002).
   PubMed Web of Science ®Google Scholar
• Noakes M, Foster PR, Keogh JB, Clifton PM. Meal replacements are as effective as structured weight-loss for treating obesity in adults with features of metabolic syndrome. J. Nutr. 134, 1894–1899 (2004).
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int. J. Obes. Relat. Metab. Disord. 27, 537–549 (2003).
   PubMed Web of Science ®Google Scholar
• Hannum SM, Carson L, Evans E et al. Use of portion-controlled entrees enhances weight loss in women. Obes. Res. 12, 538–546 (2004).
   Google Scholar
• Ditschuneit HH, Frier HI, Flechtner-Mors M. Lipoprotein responses to weight loss maintenance in high-risk subjects. Eur. J. Clin. Nutr. 56, 264–270 (2002).
   PubMed Web of Science ®Google Scholar
• Li Z, Hong K, Saltsman P et al. Long-term efficacy of soy-based meal replacements vs. an individualized diet plan in obese Type II DM patients: relative effects on weight loss, metabolic parameters, and C-reactive protein. Eur. J. Clin. Nutr.59(3), 411–418 (2005).
   PubMedGoogle Scholar
• Vidal-Guevera ML, Samper M, Martinez-Silla G et al. Meal replacement as a dietary therapy for weight. Nutr. Hosp. 19, 202–208 (2004).
   Google Scholar
• Harder H, Dinesen B, Astrup A. The effect of a rapid weight loss on lipid profile and glycemic control in obese Type 2 diabetic patients. Int. J. Obes. Relat. Metab. Disord. 28, 180–182 (2004).
   Web of Science ®Google Scholar
• Allison DB, Gadbury G, Schwartz LG et al. A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. Eur. J. Clin. Nutr. 57, 514–522 (2003).
   PubMed Web of Science ®Google Scholar
• Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes. Res. 8, 399–402 (2000).
   PubMedGoogle Scholar
• Wing RR. Food provision in dietary intervention studies. Am. J. Clin. Nutr. 66, 421–422 (1997).
   Google Scholar
• UK Prospective DiabetesStudy Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type 2 diabetic patients. Metabolism 39, 905–912 (1990).
   Google Scholar
• Wing RR, Hill JO. Successful weight loss maintenance. Ann. Rev. Nutr. 21, 323–341 (2001).
   PubMed Web of Science ®Google Scholar
• Hadden DR, Blair ALT, Wilson EZ et al. Natural history of diabetes presenting age 40–69 years: a prospective study of influence of intensive dietary therapy. Q. J. Med. 59, 579–598 (1986).
   Google Scholar
• Unsitupa M, Louheranta A, Lindstrom J et al. The Finnish Diabetes Prevention Study. Br. J. Nutr. 83(Suppl. 1), 137–142 (2000).
   Google Scholar
• Knowler WC, Barrett-Conner E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Li G, Yang W, Jiang Y et al. Effects of insulin secretion on the efficacy of interventions to retard development of Type 2 diabetes mellitus: the DA Qing IGT study and diabetes study. Diabetes Res. Clin. Pract. 58, 293–200 (2002).
   Google Scholar
• Cox KL, Burke V, Morton AR, Beilin LJ, Puddey IB. Independent and additive effects of energy restriction and exercise on glucose and insulin concentrations in sedentary overweight men. Am. J. Clin. Nutr. 80, 308–316 (2004).
   PubMed Web of Science ®Google Scholar
• Eriksson K-F, Lindgarde F. Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 34, 891–898 (1991).
   PubMed Web of Science ®Google Scholar
• Institutes of Health,National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH, MD, USA (1998).
   Google Scholar
• Thompson PD, Buchner D, Pina IL et al. Exercise and physical activity: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, an Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 107, 3109–3116 (2003).
   PubMed Web of Science ®Google Scholar
• NIH Consensus DevelopmentPanel on Physical Activity and Cardiovascular Health. Physical activity and cardiovascular health. JAMA 276, 241–246 (1996).
   Google Scholar
• Visona C, George VA. Impact of dieting status and dietary restraint on post exercise energy intake in overweight women. Obes. Res. 10, 1251–1258 (2002)
   PubMedGoogle Scholar
• Albright A, Franz M, Hornsby G et al. American College of Sports Medicine position stand. Exercise and Type 2 diabetes. Med. Sci. Sports Exerc. 32, 1345–1360 (2000).
   PubMed Web of Science ®Google Scholar
• Dela F, vonLinstow ME, Mikines KJ, Galbo H. Physical training may enhance β-cell function in Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 287, E1024–E1031 (2004).
   PubMed Web of Science ®Google Scholar
• Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in Type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 286, 1218–1227 (2001).
   PubMed Web of Science ®Google Scholar
• Troseid M, Lappegard KT, Claudi T et al. Exercise reduces plasma levels of the chemokines MCP-1 an IL-8 in subjects with the metabolic syndrome. Eur. Heart J. 25(4), 349–355 (2004).
   PubMedGoogle Scholar
• Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim. Care Clin. Office Pract. 30, 465–491 (2003).
   PubMed Web of Science ®Google Scholar
• Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metab. Disord. 26, 262–273 (2002).
   PubMed Web of Science ®Google Scholar
• McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 56, 1093–1124 (1998).
   PubMed Web of Science ®Google Scholar
• McNulty SJ, Ur E, Williams G. The Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 26, 125–131 (2003).
   PubMed Web of Science ®Google Scholar
• Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to hypocaloric diet: a systematic review of randomized clinical trials. Am. J. Clin. Nutr. 80, 1461–1468 (2004).
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjostorm L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of diabetes. Diabetes Care 27, 155–161 (2004).
   PubMed Web of Science ®Google Scholar
• Didangelos TP, Thanopoulou AK, Bousboulas SH et al. The ORLIstat and CAcardiovascular risk profile in patients with metabolic syndrome and Type 2 DIAbetes (ORLICARDIA) Study. Curr. Med. Res. Opin. 20, 1393–401 (2004).
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr. Metab.17, 222–229 (2004).
   PubMedGoogle Scholar
• Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 290, 486–494 (2003).
   PubMed Web of Science ®Google Scholar
• Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in Type 2 diabetes mellitus: background paper for the American College of Physicians. Ann. Int. Med. 140, 650–658 (2004).
   PubMed Web of Science ®Google Scholar
• Medical Research Council/British Heart Foundation. Heart Protection Study of cholesterol lowering with simvastatin in 29536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic B-cell function and preservation of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51, 2796–2803 (2002).
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Parving H-H, Pederson O. Intensified multifactorial intervention in patients with Type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353, 617–622 (1999).
   PubMed Web of Science ®Google Scholar
• Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim. Care Clin. Office Pract. 30, 465–491 (2003).
   PubMed Web of Science ®Google Scholar
• Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagons-like peptide-1 in Type 2 diabetes. J. Clin. Endocrinol. Metab. 86, 3853–3860 (2001).
   PubMed Web of Science ®Google Scholar
• Jones KB. Experience with the Roux-en-Y gastric bypass, and commentary on current trends. Obes. Surg. 10, 183–185 (2000).
   PubMed Web of Science ®Google Scholar
• MacDonald KG, Long SD, Swanson MS et al. The gastric bypass operation reduces the progresson and mortality of non-insulin-dependent diabetes mellitus. J. Gastrointest. Sur. 1, 213–220 (1997).
   PubMedGoogle Scholar
• Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683–2693 (2004).
   PubMed Web of Science ®Google Scholar
• Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Sys Rev. CD004094 (2004).
   Google Scholar
• Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292(14), 1724–1737 (2004).
   PubMed Web of Science ®Google Scholar
• Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J. Pediatr. Endocrinol. Metab. 15(Suppl. 2), 737–744 (2002).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 21, 296–309 (1998).
   PubMed Web of Science ®Google Scholar
• Stockmeyer C, Kuester A, Ramsey D et al. National Nutrition Summit, May 30, 2000: results of the obesity discussion groups. Obes. Res. 9, S41–S52 (2001).
   Google Scholar
• Internal Revenue Service. Medical and Dental Expenses. IRS Publication 502. US Government Printing Office, DC, USA (2002).
   Google Scholar
• Rothacker DQ. Five-year self-management of weight using meal replacements: comparison with matched controls in rural Wisconsin. Nutrition 16, 344–348 (2000).
   Google Scholar
• Ryan DH, Espeland MA, Foster GD et al. Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in Type 2 diabetes. Control Clin. Trials 24, 610–628 (2003).
   PubMedGoogle Scholar
• Ball SD, Keller KR, Moyer-Mileur LJ, Ding Y-W, Donaldson D, Jackson WD. Prolongation of satiety after low versus moderately high glycemic index meals in obese adolescents. Pediatrics 111, 488–494 (2003).
   Google Scholar
• Reynolds LR, Konz EC, Federich RC, Anderson JW. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing Type 2 diabetes mellitus. Diabetes Obes. Metable. 4, 270–275 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O’Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes. Res. 10, 633–641 (2002).
   PubMedGoogle Scholar
• Ashley JM, St. Jeor ST, Perumean-Chaney S, Schrage J, Bovee V. Meal replacements in weight interventions. Obes. Res. 9, 312S–317S (2001).
   Google Scholar
• Yip I, Go VLW, DeShields S, Saltsman P et al. Liquid meal replacement and glycemic control in obese Type 2 diabetic patients. Obes. Res. 9, 341S–347S (2001).
   PubMedGoogle Scholar
• Mazzone T. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance. Am. J. Cardiol. 93, 27C–31C (2004).
   Web of Science ®Google Scholar
• Waitman JA, Aronne LJ. Pharmacotherapy of obesity. Obesity Management 1, 15–19 (2005).
   Google Scholar